Percutaneous coronary intervention (PCI) is a therapy to reduce angina and improve quality of life in patients with stable ischemic heart disease. However, it is unclear whether the quality of life after PCI is more dependent on the PCI or other patient-related factors. To address this question, we created models to predict angina and quality of life 1 year after PCI and medical therapy.
S
table ischemic heart disease (SIHD) is a common clinical situation that is managed with aggressive medical therapy, with or without coronary revascularization. 1 However, it is not clear to what extent the severity of angina during follow-up is dependent on whether a patient is revascularized, as compared with other patient characteristics. 2, 3 Prediction models from clinical trials can be used to support precision medicine by enabling the results of a trial to be applied to individual patients based on their unique constellation of demographic and clinical factors. 4, 5 Developing such prediction models for patients with SIHD is a critical first step in developing strategies to better inform clinicians about outcomes and thereby enhance decision-making and allowing providers to share with patients the risks and benefits of treatment options. 6, 7 Given that percutaneous coronary intervention (PCI) offers no reduction in the risk of mortality or myocardial infarction over optimal medical therapy (OMT) alone, it is important to develop models that can estimate patients' symptoms and quality of life outcomes, where PCI has benefit but other factors may also be important. 1, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] By combining such models with estimates of the periprocedural risks associated with PCI, [20] [21] [22] [23] patients and their physicians could have the information needed to make an informed decision. Currently, no risk models exist to predict SIHD patients' health status (their symptoms, function, and quality of life) after OMT with or without PCI.
To address this gap in knowledge, we used data from the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation), a large randomized trial of OMT with or without PCI, to build prediction models of patients' health status outcomes using the disease-specific Seattle Angina Questionnaire (SAQ). 24, 25 Creating such models can enable physicians to better share with patients the estimated benefits of revascularization and improve a known deficiency in patients' understanding. [26] [27] [28] [29] It would also align closely with the Institute of Medicine's vision for more efficient, evidencebased, personalized healthcare 30 and could lay the foundation for better-informed consent processes. 31, 32 
METHODS
The data, and study materials cannot be made available, per Veterans Affairs policy, to other researchers for purposes of reproducing the results or replicating the procedure.
Trial Overview
The COURAGE trial randomized 2287 patients with the stable coronary disease to OMT with or without upfront PCI between 1999 and 2004 at 50 United States and Canadian centers. The detailed methods of the trial have been previously described. 33, 34 In summary, the main results from COURAGE demonstrated that a strategy of upfront PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, but did improve patients' angina and quality of life over at least 2 years of observation. 16, 17, 34 After local Institutional Review Board approval, patients who were eligible for the study underwent randomization after providing written informed consent.
Outcomes and Potential Predictors of Health Status Outcomes
Patients' health status, a key secondary outcome in the COURAGE trial, was assessed with the disease-specific SAQ at the time of randomization and at 1, 3, 6, and 12 months, and annually thereafter until the end of the trial. The SAQ is a valid and sensitive 19-item health status assessment comprising 5 domains of coronary artery disease: physical limitation, angina stability, angina frequency, treatment satisfaction, and quality of life. 24, 25, 35 Scores in each domain range from 0 to 100, with higher scores indicating better health status.
The 3 most clinically relevant scales of the SAQ are the angina frequency, physical limitation, and quality of life domains. The angina frequency domain quantifies the frequency of angina over the preceding month, ranging from >4× per day (a score of 0) to no angina (a score of 100). The physical limitation domain assesses how daily activities, such as dressing, walking, or strenuous activities, are restricted by angina, whereas the quality of life domain assesses patients' perspectives of how their angina limits their quality of life. A score of 0 indicates very poor physical limitation or quality of life and a score of 100 indicates excellent disease-specific function or quality of life.
We selected 1-year health status, as assessed by the SAQ, as the primary outcome in this analysis because of its clinical relevance and its perceived utility as a foundation for shared
WHAT IS KNOWN
• Aggressive medical therapy can be used to manage stable ischemic heart disease, with or without percutaneous coronary intervention (PCI).
• In stable ischemic heart disease, the principal benefit of PCI is improved angina and quality of life, but the benefits for individual patients from the use of PCI in addition to aggressive medical therapy is unknown.
WHAT THE STUDY ADDS
• Patients' health status outcomes 1 year after initial treatment with PCI plus aggressive medical therapy or with medical therapy alone can be predicted with modest accuracy.
• The health status outcomes, based on the Seattle Angina Questionnaire, are consistently better with PCI, although the benefits are small, especially when compared with their baseline health status.
• Developing tools to share with patients their 1-year angina and health status to improve shared medical decision-making should be prospectively tested to illuminate their benefit in improving the patient-centeredness and value of PCI. medical decision-making. One-year outcomes reflect a clinical balance between giving both treatment strategies a chance to achieve their benefits and the desire to address patients' shorter-term health status. It also represents a midpoint in the differences observed between PCI+OMT and OMT alone over time in the COURAGE trial. 17 To predict patients' angina-related health status, we examined potential predictor variables that are readily available when considering PCI. These included demographic characteristics (age, gender, race), baseline SAQ scores, smoking status, comorbidities (body mass index, hypertension, diabetes mellitus, congestive heart failure, transient ischemic attack, prior myocardial infarction and treatment factors (baseline antiplatelet therapy, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, calcium channel blockers, long-acting nitrates, and lipid-lowering agents). The Duke Jeopardy Score, the magnitude of myocardium subtended by narrowed or occluded coronary arteries, was included in the analysis to summarize patients' angiographic severity. It ranges from 0 to 12, with higher scores indicating greater amounts of myocardium at risk.
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Statistical Analysis
The distribution of scores in each domain was described with means, medians, interquartile ranges, and ranges. One-year SAQ scores in each of the 3 domains were the primary outcome and were analyzed independently. The Kruskal-Wallis test was used to compare means and medians, and the χ 2 statistic was used to compare proportions by individual patient characteristics and treatment.
An important aspect in the analysis of disease-specific health status scores is that they have a natural upper bound (a score of 100), which is the therapeutic goal of treating SIHD (ie, to eliminate angina and its associated physical function and quality of life limitations). Accordingly, SAQ scores are often highly skewed. However, when building regression models with a scale from 0 to 100, ceiling values (eg, 100) are inherently problematic, often leading to the possibility that the defined boundary is silently exceeded. In addition, and congruent with clinical experience, an upper limit of 100 on the SAQ at baseline indicates no room for treatment benefit, as a patient is already enjoying perfect health status (100). 37 To address this methodological challenge, we thoroughly evaluated different modeling strategies for predicting continuous 1-year health status outcomes. We first described the distribution of SAQ scores in each domain and then explored alternative models, including linear regression, Tobit regression with gamma or exponential distributions in which a threshold of 100 was used and the linear effect was on the uncensored latent variable and not on the observed outcome, zero-inflated, median regression, and censored least absolute deviations to distribution models. 38 After fitting alternative models, actual SAQ scores were back-converted from the models' estimates. We then used multiple methods to assess model performance and select the best fitting models. First, mean and median observed SAQ scores and predicted SAQ scores in each domain were examined. Then, predicted SAQ scores were divided into deciles and paired Student t tests and calibration curves were used to compare median predicted deciles of SAQ scores to the observed medians of each decile. Third, to measure the variance in SAQ scores in each domain explained by the models, coefficients of determination (R 2 ), which are equal to the square of the correlation coefficient between the individual predicted SAQ scores and the observed SAQ scores were calculated and compared.
For each health status domain (angina frequency, physical limitation, and quality of life), clinically relevant predictor variables, chosen from patients' baseline characteristics and clinical risk factors, were evaluated with both univariate and multivariable models. Variable selection was performed with a backward selection process by removing variables with a P value >0.3. To reflect the strength of association between model variables and SAQ scores-outcomes, estimates versus actual means, and absolute prediction errors were used to describe the performance of the alternative modeling strategies. 39 Nonlinear associations (eg, splines or polynomial functions) between predictor variables and outcomes and interactions with treatment were explored, but did not improve model performance and were not included in the final models.
To help facilitate interpretation of the models and provide more actionable decision-making tools for patients and providers, SAQ scores were also categorized. SAQ physical limitation and quality of life scores were grouped into very good to excellent (75-100) or less good (<75), as has been done in prior prediction models of patients' health status. 40 Angina frequency scores were grouped into the presence of any angina at 1 year (0-99), as compared with no angina (100). 41 Logistic regression models were then constructed to identify patient characteristics independently associated with favorable 1-year SAQ scores in each domain and their discrimination was assessed with the calculation of the C statistic. 42 Finally, to better support use of the models in clinical care, we created more parsimonious models that would require fewer predictor variables, avoid potential overfitting, and would be more feasible to deploy in routine clinical care. This was accomplished using Harrell backward selection strategy to identify those variables providing the greatest prognostic value, in addition to log-likelihood functions, Akaike's Information Criteria and Bayesian Information Criteria values. 42 To do this, the contribution of each covariate in the multivariable model was ranked by F value and the variables with the smallest contribution to the model were sequentially eliminated until further variable elimination led to a >10% loss in model prediction, as compared with the initial model. This insured that the remaining covariates explained >90% of the variance of the full model. The final parsimonious models are presented. Also, we performed the purposeful selection method to examine the final parsimonious models. 43, 44 Missing baseline data were ≈16% and were imputed using multiple multivariate imputations by chained equations. 45 No imputation of SAQ outcomes at 1 year was performed, but the characteristics of those with and without missing data were compared (Tables I through  III in the Data Supplement) . To internally validate these models, we performed bootstrap resampling for 500 replications and assessed the performance via calibration slopes and C-indices on the bootstrapped data and validated on the original data set for each domain. The mathematical methods to estimate health status are presented in the Data Supplement. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Population Characteristics
Of 1149 patients randomized to PCI plus OMT, the number of patients who had angina frequency, physical limitation, and quality of life SAQ scores at 1 year were 844, 863, and 862, respectively. Of 1138 patients randomized to OMT alone, the corresponding numbers were 812, 829, and 827. After excluding patients who had died by 1 year (n=118), the percentages of patients missing SAQ scores in physical limitation, angina frequency, and quality of life were 25% and 20%, 23% and 24%, and 20% and 22% in the PCI plus OMT and OMT alone groups, respectively. Tables I through III in the Data Supplement show the differences in the patient populations with and without 1-year SAQ scores. Those without 1-year follow-up were more likely to have had a prior PCI, to have smoked at baseline, and to be less physically active. In contrast, those with follow-up were less likely to have a history of congestive heart failure. There were no statistically significant differences in age, gender, race, diabetes mellitus, hypertension, prior myocardial infarction, or the Duke Jeopardy Score. Most importantly, the baseline SAQ scores did not differ between those with and without follow-up. The distributions of SAQ scores by treatment groups in each domain are shown in Figure 1 (kernel smoothed density graphs shown in Figure I in the Data Supplement). Table 1 summarizes the variations in angina-related health status by treatment group at baseline and 1 year. All scores improved substantially in both groups, but slightly more with PCI for the SAQ angina frequency and quality of life domains. Table 2 shows the predictive accuracy of each model in terms of absolute prediction errors between actual and predicted values for 1-year SAQ scores on the basis of fitting different models. Although a Tobit model with a gamma distribution had the lowest absolute prediction error (7.63) best fit SAQ angina frequency scores, the censored least absolute deviation model best fit the physical limitation and quality of life domains with the lowest absolute prediction error of 9.29 and 11.07, respectively. For internal model validation, the calibration slope and C-indices in each health status domain were similar after internal bootstrap validation.
Identifying the Best Modeling Strategy for Continuous Health Status Outcomes
Predictors of 1-Year Angina
The final model to predict patients' 1-year angina frequency as a continuous variable is shown in the second column of Table 3 . Baseline angina frequency was the strongest predictor of 1-year angina outcomes (mean difference in 1-year SAQ scores of 2.29±0.2/10-point higher baseline SAQ angina frequency score); followed by age, diabetes mellitus status, the Duke Jeopardy Score, and medications including aspirin and nitrates. PCI was associated with significantly higher 1-year angina frequency scores (2.39±1.01 PCI versus OMT; 95% CI, 0.74-4.72), but the magnitude of the effect was small. Importantly, there were no significant interactions, suggesting a consistent benefit of PCI across myriad patient characteristics, including baseline angina frequency. The proportion of the variance explained by PCI was smaller than that of the other patient factors (0.07 versus 0.29). This model exhibited good calibration, with the agreement between observed outcomes and predictions of 0.83, suggesting that 83% of the variation in observed deciles was explained by the model ( Figure IIA in the Data Supplement).
At 1 year, 56.8% of patients in the PCI group and 49.9% in the OMT group were angina-free (Table 4) . The odds ratios (ORs) for being angina-free in the model are shown in Figure 2 . The most important factors associated with being angina-free at 1 year were baseline angina frequency (OR, 1.21/10-point higher baseline SAQ angina frequency score; 95% CI, 1.15-1.27), diabetes mellitus, the Duke Jeopardy Score, and baseline medication use, including aspirin, nitrates, and lipid- 
Predictors of 1-Year Physical Limitation Because of Angina
The final model to predict patients' 1-year SAQ physical limitation scores as a continuous variable is shown in the third column of Table 3 . Baseline SAQ physical limitation score was the strongest predictor of 1-year outcomes, for which each 10-point higher baseline SAQ physical limitation score was associated with a 4.12±0.23-point increase in 1-year score. Other important predictors included age, diabetes mellitus, heart failure, prior transient ischemic attack, prior MI, the Duke Jeopardy Score, and baseline medications. Treatment with PCI was not significantly associated with 1-year physical limitations because of angina (mean benefit of adding PCI to OMT was 0.27±1.1 points on the 1-year SAQ physical limitation score [P=0.81; Figure 
Predictors of 1-Year Quality of Life
The final model to predict patients' 1-year SAQ quality of life scores as a continuous variable is shown in the fourth column of Table 3 . The strongest predictor of 1-year quality of life was patients' baseline SAQ quality of life scores (2.32±0.23 points/10 points; P<0.0001). Other significant predictors included age, diabetes mellitus, a history of transient ischemic attack, baseline use of aspirin or calcium channel blockers, the Duke Absolute prediction error (summarized by the median and first quartile to the third quartile). OMT indicates optimal medical therapy; and PCI, percutaneous coronary intervention. Jeopardy Score, and smoking status. PCI was associated with a mean improvement of 2.2±1.1 points in 1-year SAQ quality of life score, but again, there were no significant interactions between PCI and any of the patient factors. The proportion of the variance explained by PCI was smaller than that of the other patient factors (0.05 versus 0.24). The model had excellent calibration with the agreement between observed outcomes and predictions of 0.90, suggesting that 90% of the variation in observed deciles was explained by the model ( Figure  IVA in the Data Supplement). At 1 year, 65.6% in the PCI group and 58.5% in the OMT group had very good/excellent quality of life (Table 4 ). Figure 4 shows the ORs of a very good/excellent quality of life at 1 year. The strongest predictors of favorable quality of life were baseline SAQ quality of life (OR, 1.23/10-point higher baseline SAQ quality of life score; 95% CI, 1.17-1. 
DISCUSSION
We have shown that at 1-year patients treated with PCI plus OMT will have less angina and better quality of life than patients treated with OMT alone. However, other factors, such as baseline severity of angina, age, the magnitude of myocardium subtended by narrowed coronary arteries and diabetes mellitus are also strongly associated with 1-year health status. Indeed, although PCI did result in improved quality of life, the changes in the 3 SAQ domains of angina frequency, physical limitation, and quality of life improved only modestly with PCI plus OMT compared with OMT alone. Given a growing recognition of the need to engage patients in shared decision-making, there is a need to develop tools to provide individualized estimates of outcomes so that patients and their physicians can better understand how different treatment approaches might affect a particular patient. The treatment of SIHD is a prototypical example of such a situation in that PCI is not expected to improve survival, but may improve symptoms, function, and quality of life. Using the largest randomized trial of PCI in stable coronary artery disease, we found that the majority of patients in both PCI+OMT and OMT alone groups experienced substantial improvements in their angina-related health status 1 year after randomization. Although there were substantial variations in 1-year health status across different domains that could be predicted by patient characteristics, PCI offered only a very small improvement over OMT alone. These results from COURAGE can help clinicians support shared decision-making with their patients by directly estimating the modest improvements in outcomes with PCI.
Despite the growing emphasis on evidence-based medicine and the importance of engaging patients in shared decision-making, it is inherently difficult to apply the results of clinical trials to individual patients in routine clinical care. For example, the COURAGE trial demonstrated no difference in survival or myocardial infarction rates in OMT-treated SIHD patients with or without upfront PCI. Although both groups' health status improved substantially over time, there was a modest overall improvement in patients' health status with PCI across the entire population. 17 Yet, for an individual patient, expected outcomes with and without upfront PCI cannot be readily gleaned from the average benefit seen across the entire COURAGE population and high variability in individual patients' outcomes is expected. Thus, we created models to support the use of the COURAGE data to personalize the estimates of individual patients' health status outcomes so that personalized, shared decision-making could occur. We found that baseline SAQ scores, antianginal medication, the magnitude of myocardium subtended by narrowed coronary arteries, and a few other demographic characteristics, such as age and diabetes mellitus, can help estimate patients' outcomes. Surprisingly, we did not find any interactions between the use of PCI and other patient characteristics. This means that the small benefits of PCI on individual patients were similar, regardless of age, the presence of diabetes mellitus or baseline angina.
This approach extends work done in clinical trials of thrombolytic therapy for acute ischemic stroke 46 and thienopyridine therapy in the setting of PCI for an acute coronary syndrome. 47 In these prior efforts, a similar approach was used to develop individualized outcomes estimates based on the results of large clinical trials so that the benefits of therapy could be individualized to specific patients. The C statistics of these models ranged from 0.68 to 0.82, which were similar to the ones we found in predicting health status outcomes in patients with SIHD eligible for PCI from COURAGE. Further supporting the potential value of the models we developed in improving clinical care, prior work has suggested that C statistics >0.60 are beneficial in supporting individualized estimates of outcomes, which is substantially lower than the discriminatory performance of our models (0.71-0.81). 4 Our effort to predict long-term health status outcomes has been done, to our knowledge, only in the setting of acute myocardial infarction 40 and in patients undergoing PCI, but without a comparison of outcomes with OMT alone. 41 A feature of the proposed models for assisting shared decision-making is that the relative benefits of PCI were consistent in all models and did not differ by patient characteristics. Thus, although knowing expected angina or health status can be very beneficial in calibrating patients' expectations, and reassuring them that they are likely to improve regardless of treatment, the absolute benefits of PCI were modest and when balanced against the periprocedural risks of PCI, many may choose to first determine their outcomes with OMT alone, rather than accept the periprocedural risks and costs of PCI. Clinical examples of how the models might inform such discussions are provided in the Data Supplement.
Given the recently published ORBITA trial (PCI in stable angina), some may question whether the observed differences in outcomes with PCI could be attributable to a placebo effect. ORBITA was a double-blind trial of 200 patients with SIHD randomized to PCI or sham procedure that was powered with exercise time as the primary end point. 48 ORBITA found that PCI compared with the sham procedure did not significantly increase exercise time. However, there was a nonsignificant difference favoring PCI in the SAQ angina frequency domain, which was quite comparable to the effect size seen in COURAGE, suggesting a true benefit of PCI in patients' perceptions of their symptoms. However, the small sample size of ORBITA precluded a definitive assessment of the impact of PCI on patients' health status and the data presented here are not only consistent with ORBITA but also represent the largest clinical trial available with which to build such estimates of patients' outcomes. There are some limitations of this study that should be considered. There are variations in SAQ scores among patients that persist even after adjusting for patient demographics, clinical factors, and medications at baseline. This may reflect variations in SAQ score measurements, or other patient factors not measured in the COURAGE trial, such as variations in the completeness of revascularization. Importantly, it can also reflect the use of postrandomization treatments, such as crossover to coronary revascularization in the OMT arm, different use of antianginal medications over time, and other factors that influence outcomes over the year after an initial treatment strategy is pursued, although these treatments could not be known at the time an initial decision needs to be made. 49 A second limitation is that 20% to 25% of patients' SAQ scores were missing at 1 year, potentially introducing a selection bias. Moreover, the magnitude of baseline ischemia was not available in all patients and may contribute to 1-year health status outcomes, however, this should be strongly associated with the Duke Jeopardy Score that was included in the models. Of note, the inclusion and exclusion criteria of the COURAGE trial may limit the generalizability of our findings to all patients, although the random allocation of PCI is a great strength of our study and eliminates many of the selection biases inherent in observational studies. Replication of this work, and validation of these models, in a broader population is an important avenue for future research. Another potential limitation is that the COURAGE trial was conducted 15 years ago and used exceedingly good medical therapy and for the models to be relevant in medical decision-making, changes in treatments and the use of similarly high-quality medical therapy may limit the accuracy of the models in current care. 50 In addition, there are practical barriers to overcome if these models are to be used to calculate expected outcomes in individual patients. These include the need to collect the SAQ (although a 7-item version is available) 51 and the widespread practice of ad hoc PCI following coronary angiography that limits the time for detailed discussions of the potential benefits and risks of PCI, particularly given the inclusion of the Duke Jeopardy Score in our models. However, the model can be used for shared decision-making when consent is obtained for cath and PCI preprocedure if the model without the Duke Jeopardy Score is used (Figures V through VII in the Data Supplement). Although shared medical decision-making about PCI may be problematic in the cath laboratory setting, it may be more feasible after computed tomography angiography when coronary anatomy is known but immediate PCI cannot be performed. Finally, some important predictors of outcome, such as socioeconomic status, were not measured and future efforts to further improve these prediction models are warranted.
CONCLUSIONS
We have developed models to show the strength of association between a range of patient characteristics and health status outcomes 1 year after initial treatment with PCI plus OMT or OMT alone. However, the benefit with PCI was modest, and other patient characteristics were equally, or more, important in predicting outcomes. Indeed, demographic variables, comorbidities, and medications are associated with patients' 1-year health status, with the most important factor being patients' baseline symptoms, function, and quality of life. Using prediction models to estimate patientcentered health status outcomes could be used as an evidence-based foundation for improved shared medical decision-making in SIHD and should be tested in future studies.
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